News

ivWatch Extends Its Global Reach Signing Three New Distribution Partners

Newport News, VA, ivWatch, LLC, an innovative IV safety company working to eliminate harm caused by infiltration and extravasation events, announced three new strategic distribution partnerships internationally. Bameco in Austria, Warba Medical Supplies in Kuwait, and Mustafa Sultan Science & Industry Co, LLC in Oman have each signed exclusive agreements to promote, sell, and support ivWatch’s continuous monitoring products in their markets. ivWatch’s novel technologies will complement and bolster their existing portfolios of intravenous products provided to hospitals and other health care facilities.

ivWatch solutions continue to be available in more countries throughout the globe and with the addition of Austria, Kuwait, and Oman, clinicians will now be able to improve their bedside decision-making with real-time IV infiltration data. Continuous IV site monitoring provides accurate and precise insights to detect infiltrations and extravasations at their earliest stages. ivWatch’s proprietary algorithm detects infiltrations promptly and notifies clinicians of adverse IV therapy events often hours before they are detectable by visual or tactile examination.1

“At ivWatch, we are on a steadfast mission to improve IV safety globally and we are extremely passionate about partnering with likeminded innovators who share that same relentless pursuit to advance patient safety,” said Chuck Egress, Vice President of Business Development and Emerging Markets at ivWatch. “IV infiltrations and extravasations are a major global patient safety concern, and these new partnerships provide increased access to advanced safety solutions to help end complications and improve patient outcomes in IV therapy.”

ivWatch has over 60 patents worldwide and received its first FDA clearance in 2015 for its IV site monitoring system that consists of an ivWatch Patient Monitor and a reusable optical biosensor that uses visible and near-infrared light to continuously measure changes in the optical properties of the tissue near an IV insertion site. In 2020, the company expanded its portfolio of sensor solutions and received FDA clearance for a single-use, miniaturized biosensor that is cleared for all patient age groups, sizes, and skin tones. Both sensors work seamlessly with the intuitive user interface on the Patient Monitor, which issues audible and visual “Check IV” alerts for the clinician to assess the IV site. ivWatch technology performs with high accuracy, intelligence, and low false alarm rates, which is critical to improving patient outcomes.

Read more here.

Recent News

02/22/2024

Protected: Don’t Miss These Spring Talent Events

There is no excerpt because this is a protected post.

02/21/2024

SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub

SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023. “Hundreds of organizations have been selected to join each network.

02/21/2024

ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announced enrollment of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071, an investigational new drug based on ReAlta’s novel EPICC peptide